FLT3 mutations have no prognostic impact in elderly patients with acute myeloid leukemia and normal karyotype.

摘要: The clinical outcome of acute myeloid leukemia (AML) is extremely variable, ranging from survival a few days to cure [1-3]. In the recent years, different biological features at presentation have been reported as useful for prediction outcome; in particular, nonrandom clonal chromosome aberrations, which are detectable leukemic cells approximately 50% adult AML patients, not only diagnostic markers specific subtypes but also provide prognostic information achievement complete remission (CR), relapse risk, and [4-7]. Accordingly, pretreatment cytogenetics represent part routine diagnostics patients with new World Health Organization classification hematologic malignancies takes into account aberrations their molecular counterparts together morphology, immunophenotype, [8]. Despite continuous improvements cytogenetic methodology, microscopically abnormalities found normal karyotype usually classified intermediate-risk category [9,10]; this patient subset, very heterogeneous 5-year rates vary between 25% 45% studies. As consequence, it utmost importance discriminate within subgroup subjects characteristics diagnosis [11―14].